Nicotinell Tts 30

Nicotine, the active ingredient in Nicotinell Tts 30, is a nicotine replacement therapy presented as a 30 mg transdermal patch for transdermal use. It treats smoking cessation in adults who want to quit. GNH USA supplies Nicotinell Tts 30 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicotinell Tts 30 is a nicotine replacement therapy used in the management of nicotine dependence.

Smoking cessation: assists adult smokers in quitting by delivering a steady dose of nicotine. Tobacco dependence: provides controlled nicotine to reduce cravings during a quit attempt. Relapse prevention: helps maintain abstinence after initial cessation by stabilizing nicotine levels.

The patch may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Skin irritation at the application site - Itching or redness where the patch is applied - Headache - Nausea - Dizziness - Sleep disturbance or vivid dreams

Serious or Rare Side Effects: - Severe allergic reaction (rash, swelling, difficulty breathing) - Significant hypotension or tachycardia - Chest pain or palpitations - Syncope (fainting) - Severe skin blistering or ulceration

Before using Nicotinell Tts 30, consider the following safety measures.

Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina. Hypertension monitoring: use with caution in patients with high blood pressure. Concurrent nicotine products: avoid using other nicotine replacement therapies simultaneously. Pregnancy and lactation: consult a healthcare professional before use. Non‑smokers: not indicated for individuals who do not regularly smoke. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nicotinell Tts 30 can interact with certain medicines and conditions.

Major Interactions (Avoid): - Use of multiple nicotine replacement products: risk of nicotine overdose. - Recent myocardial infarction or unstable angina: may increase cardiac workload.

Moderate Interactions (Monitor Closely): - CYP1A2 substrates (e.g., theophylline, clozapine): nicotine may induce metabolism, monitor drug levels. - Beta‑blockers: nicotine‑induced tachycardia may be masked, observe heart rate. - Antidepressants such as bupropion: combined use may raise seizure risk. - Alcohol consumption: may enhance nicotine cravings, monitor usage.